We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Roche to conclusions

12 Jan 2015 By Robert Cyran

The Swiss drugs giant is paying about $1 bln for up to 56 pct of cancer testing firm Foundation Medicine. The structure echoes its success taking control of Genentech in 1990 and leaving it independent. A whopping 109 pct premium reflects Roche’s mistake of low-balling Illumina.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)